Stockreport

AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF NORTH CHICAGO, Ill., Sept. 20, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FD [Read more]